Amgen's Phase III trial of Imdelltra in treating small cell lung cancer patients met its primary endpoint of improving overall survival. The therapy targets DLL3 protein and activates T cells to destroy cancer cells, showing promising clinical benefits.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing